Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
09:21am, Wednesday, 06'th Aug 2025
Royalty Pharma (RPRX) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $0.96 per share a year ago.
Royalty Pharma Reports Second Quarter 2025 Results
07:00am, Wednesday, 06'th Aug 2025
Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised full year 2025 guidance: Portfolio Receipts expected t
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
10:15am, Tuesday, 05'th Aug 2025
Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metr
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 30'th Jul 2025
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma Declares Third Quarter 2025 Dividend
08:15am, Friday, 18'th Jul 2025
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordina
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
08:15am, Thursday, 17'th Jul 2025
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediat
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
04:15pm, Wednesday, 16'th Jul 2025
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S.
Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline
05:23am, Tuesday, 01'st Jul 2025
Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pi
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
07:19am, Tuesday, 24'th Jun 2025
Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonras
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
07:05am, Tuesday, 24'th Jun 2025
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
04:15pm, Wednesday, 04'th Jun 2025
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference
Royalty Pharma Completes the Acquisition of Its External Manager
04:30pm, Friday, 16'th May 2025
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Manageme
Royalty Pharma to Present at Upcoming Investor Conferences
08:15am, Tuesday, 13'th May 2025
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
